<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03696576</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00109224</org_study_id>
    <secondary_id>PRO18040682</secondary_id>
    <nct_id>NCT03696576</nct_id>
  </id_info>
  <brief_title>Expiratory Muscle Strength Training and Phonation Resistance Training Exercises For Elderly Patients With Vocal Fold Atrophy</brief_title>
  <official_title>EMST And PhoRTE Training For Elderly Patients With Vocal Fold Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The larynx and vocal folds undergo many age-related changes in their physiology and structure&#xD;
      that can lead to undesirable effects on the voice, with changes in the respiratory system&#xD;
      compounding these deficits. These changes, also called presbyphonia, can have serious&#xD;
      detrimental effects on the lives of elderly individuals. There are few studies that have&#xD;
      evaluated the use of voice therapy treatment options for these patients. The primary aim of&#xD;
      this study is to test whether the addition of expiratory muscle strength training (EMST) to a&#xD;
      current, validated voice therapy protocol aimed at treating presbyphonia, (phonation&#xD;
      resistance training, PhoRTE) can improve outcomes of therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to test whether the addition of EMST to PhoRTE Voice Therapy is&#xD;
      at least as effective as PhoRTE alone for improving acoustic, aerodynamic, and&#xD;
      patient-reported outcomes in patients affected by age-related vocal fold atrophy.&#xD;
&#xD;
      Voice therapy is often the first-line treatment for patients experiencing presbyphonia.&#xD;
      Despite being the most common treatment for presbyphonia, scant literature exists on the&#xD;
      efficacy of voice therapy for these patients. The current proposal aims to add to this&#xD;
      growing body of literature. In general, studies of existing voice therapy programs for&#xD;
      presbyphonia have demonstrated success in achieving improvement in aerodynamic (increased&#xD;
      subglottal pressure), acoustic (increased shimmer, jitter, and decreased noise-to-harmonics&#xD;
      ratio), and patient-centered outcomes (reduction in Voice Handicap Index scores, decreased&#xD;
      phonatory effort). Ziegler et al. conducted a study comparing a standard voice therapy, Vocal&#xD;
      Function Exercises (VFE) and Phonation Resistance Training Exercises (PhoRTE) and found that&#xD;
      both therapies improved outcomes of voice-related quality of life, but only PhoRTE gave a&#xD;
      statistically significant reduction in perceived phonatory effort. A specific therapy&#xD;
      designed to address age-related changes to respiratory system is expiratory muscle strength&#xD;
      training (EMST). EMST devices are loaded with a resistive spring which opens when a desired&#xD;
      level of expiratory pressure is reached and maintained. Maintenance of consistent subglottal&#xD;
      pressure is the foundation for phonation. EMST device training improves active expiratory&#xD;
      muscle forces required for high-pressure activities such as long utterances or loud speech in&#xD;
      vocally healthy individuals. When used in conjunction with traditional voice therapy, EMST&#xD;
      use has also shown to increase maximum phonation time, maximum expiratory pressure, dynamic&#xD;
      range, subglottal pressure, and perception of voice handicap in professional voice users over&#xD;
      traditional voice therapy alone. The theoretical underpinnings for treatment of vocal fold&#xD;
      atrophy with EMST are clear, as it addresses many of the common goals of treatment in&#xD;
      patients with presbyphonia, but it has not yet been tested as a possible adjunctive treatment&#xD;
      for patients undergoing voice therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to the pandemic, recruitment ended earlier than expected and changes were required to alter&#xD;
    data collection methods (and were approved by the IRB). Additional changes were also made to&#xD;
    the protocol to move the study to an online platform.&#xD;
  </why_stopped>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Actual">May 4, 2020</completion_date>
  <primary_completion_date type="Actual">May 4, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
    <masking_description>Speech Language Pathologists (SLPs) will not know which group the participants have been randomized to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Voice Handicap Index-10 (VHI-10) Score</measure>
    <time_frame>At each study visit through study completion; Time 0 (therapy visit 1-Baseline), follow-up week 1 (therapy visit 2), follow-up week 2 (therapy visit 3),follow-up week 3 (therapy visit 4), follow-up week 5 (follow up visit)</time_frame>
    <description>The Voice Handicap Index-10 (VHI-10) is a validated assessment instrument that quantifies patient perceptions of his or her own voice handicap. A lower score on the VHI-10 indicates perception of a lesser voice handicap than a high score. Scores range from 0 to 40.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AVI Score at Baseline and Follow up (5 Weeks)</measure>
    <time_frame>At initial therapy visit (Baseline) and final follow up-visit (Follow up - week 5)</time_frame>
    <description>The Aging Voice Index (AVI) is a validated instrument that measures quality of life in older adults with voice disorders. A higher score indicates worse quality of life. Scores range from 0 to 92.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Expiratory Pressure (MEP)</measure>
    <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
    <description>Maximum Expiratory Pressure (MEP) was measured using a handheld manometer (Micro Direct Respiratory Pressure Meter, MicroRPM, Med-Electronics, Beltsville, MD, United States) at baseline and after 5 weeks of therapy. Participants were instructed to blow with maximum force into the MicroRPM device over 10 trials, and the participant's best three trials were used to calculate their average MEP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phonatory Airflow in Speech at Baseline and 5 Weeks</measure>
    <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
    <description>Aerodynamic measures were collected and analyzed via the Phonatory Aerodynamic System 6600 (PAS; PENTAX Medical, Montvale, NJ, United States) using the first four sentences of the Rainbow Passage. Aerodynamic measures included mean airflow during voicing and number of breaths taken. The PAS captured phonatory aerodynamic functioning using a pneumotach coupled to a facemask, with external microphone. During speech, expired air flows through the pneumotach, which consists of a stainless-steel mesh screen with pressure transducers on either side. The system calculates the pressure difference across the screen to determine airflow rate. The microphone is positioned at the end of the pneumotach and internally calibrated per system specifications to represent a mouth-to-microphone distance of 15 cm. The participant sat with the facemask held snugly over their nose and mouth while they read the first fou</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Breaths at Baseline and Follow up (5 Weeks)</measure>
    <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
    <description>Aerodynamic measurement: mean number of breaths in reading of a standard passage (The Rainbow Passage).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Cepstral Spectral Index of Dysphonia (CSID) Measurements While Reading Functional Phrases at Baseline and 5 Weeks</measure>
    <time_frame>Baseline (At initial therapy visit) and final follow up-visit (week 5)</time_frame>
    <description>Cepstral Spectral Index of Dysphonia (CSID) is a multifactorial estimate of dysphonia severity that correlates with an auditory perceptual rating of overall voice severity using a 0-100 visual analog scale. Components of the algorithm include the cepstral peak prominence and its standard deviation, the low to high spectral ratio and its standard deviation. Typically, CSID limits are 0-100, but very severe voices may exceed 100, and very periodic, normal voices may be less than 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cepstral Spectral Index of Dysphonia (CSID) Measurements at Baseline and 5 Weeks</measure>
    <time_frame>Baseline (At initial therapy visit) and final follow up-visit (week 5)</time_frame>
    <description>Cepstral Spectral Index of Dysphonia (CSID) is a multifactorial estimate of dysphonia severity that correlates with an auditory perceptual rating of overall voice severity using a 0-100 visual analog scale. Components of the algorithm include the cepstral peak prominence and its standard deviation, the low to high spectral ratio and its standard deviation. Typically, CSID limits are 0-100, but very severe voices may exceed 100, and very periodic, normal voices may be less than 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Standard Reading Passage at Baseline and Follow up (5 Weeks)</measure>
    <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
    <description>Aerodynamic measurement; mean duration to complete the reading of a standard passage (The Rainbow Passage).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cepstral Peak Prominence at Baseline and 5 Weeks Follow up</measure>
    <time_frame>At initial therapy visit (Baseline) and final follow up-visit (after week 5)</time_frame>
    <description>Acoustic measurement: Cepstral Peak Prominence and its standard deviation while reading functional phrases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cepstral Peak Prominence (CPP) Fundamental Frequency (F0) at Baseline and Follow up (5 Weeks)</measure>
    <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
    <description>Acoustic measurement: CPP F0 while reading functional phrases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Fundamental Frequency in Sentence at Baseline and at 5 Weeks</measure>
    <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
    <description>Aerodynamic measurement: mean F0 in reading of a standard passage (The Rainbow Passage).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vocal Intensity at Baseline and Follow up</measure>
    <time_frame>At initial therapy visit (baseline) and final follow up-visit (week 5)</time_frame>
    <description>Acoustic measurement: mean vocal intensity in dB SPL while reading functional phrases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change In Overall Voice Severity at 5 Weeks</measure>
    <time_frame>At initial therapy visit and final follow up-visit, after week 5</time_frame>
    <description>Overall voice severity determined by Consensus Auditory Perceptual Evaluation - Voice (CAPE-V) score provided by blinded raters. The visual analog scale for overall voice severity used. Minimum score = 0, Maximum score = 100. Higher values indicate worse voice.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Voice Disorder</condition>
  <condition>Vocal Cord Atrophy</condition>
  <condition>Presbyphonia</condition>
  <arm_group>
    <arm_group_label>PhoRTE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will undergo standard PhoRTE therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PhoRTE + EMST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EMST</intervention_name>
    <description>Training of the respiratory system muscles using the EMST device.</description>
    <arm_group_label>PhoRTE + EMST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PhoRTE</intervention_name>
    <description>Completing of PhoRTE voice therapy.</description>
    <arm_group_label>PhoRTE</arm_group_label>
    <arm_group_label>PhoRTE + EMST</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 65 or older&#xD;
&#xD;
          -  Diagnosis of presbyphonia (vocal fold atrophy) made by a fellowship-trained&#xD;
             laryngologist and a voice specialized speech language pathologist&#xD;
&#xD;
          -  Willingness to be randomized to one of two treatments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any concomitant laryngeal diagnoses or diseases known to affect voice function,&#xD;
             including: amyloidosis, arytenoid dislocation, laryngeal cancer, cricoarytenoid&#xD;
             fixation, vocal fold cyst(s), vocal nodules, vocal fold polyp(s), dysplasia, vocal&#xD;
             fold fibrous mass(es), glottal web, vocal fold immobility, laryngeal stenosis,&#xD;
             laryngocele, leukoplakia, Parkinson's disease, Reinke's edema, respiratory recurrent&#xD;
             pneumonia, sarcoidosis, spasmodic dysphonia&#xD;
&#xD;
          -  Any chronic lower airway disease such as chronic obstructive pulmonary disease (COPD),&#xD;
             asthma, chronic bronchitis, emphysema, cystic fibrosis&#xD;
&#xD;
          -  History of acute stroke&#xD;
&#xD;
          -  Untreated hypertension&#xD;
&#xD;
          -  Untreated gastroesophageal reflux disease (GERD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Gillespie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Voice Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kost K, Parham K. Presbyphonia: What can be done? Ear Nose Throat J. 2017 Mar;96(3):108-110.</citation>
    <PMID>28346640</PMID>
  </reference>
  <reference>
    <citation>Polkey MI, Harris ML, Hughes PD, Hamnegärd CH, Lyons D, Green M, Moxham J. The contractile properties of the elderly human diaphragm. Am J Respir Crit Care Med. 1997 May;155(5):1560-4.</citation>
    <PMID>9154857</PMID>
  </reference>
  <reference>
    <citation>Janssens JP, Pache JC, Nicod LP. Physiological changes in respiratory function associated with ageing. Eur Respir J. 1999 Jan;13(1):197-205. Review.</citation>
    <PMID>10836348</PMID>
  </reference>
  <reference>
    <citation>Skloot GS. The Effects of Aging on Lung Structure and Function. Clin Geriatr Med. 2017 Nov;33(4):447-457. doi: 10.1016/j.cger.2017.06.001. Epub 2017 Aug 19. Review.</citation>
    <PMID>28991643</PMID>
  </reference>
  <reference>
    <citation>Thomas LB, Harrison AL, Stemple JC. Aging thyroarytenoid and limb skeletal muscle: lessons in contrast. J Voice. 2008 Jul;22(4):430-50. Epub 2007 Jan 22. Review.</citation>
    <PMID>17241767</PMID>
  </reference>
  <reference>
    <citation>Takano S, Kimura M, Nito T, Imagawa H, Sakakibara K, Tayama N. Clinical analysis of presbylarynx--vocal fold atrophy in elderly individuals. Auris Nasus Larynx. 2010 Aug;37(4):461-4. doi: 10.1016/j.anl.2009.11.013. Epub 2009 Dec 28.</citation>
    <PMID>20036792</PMID>
  </reference>
  <reference>
    <citation>Davids T, Klein AM, Johns MM 3rd. Current dysphonia trends in patients over the age of 65: is vocal atrophy becoming more prevalent? Laryngoscope. 2012 Feb;122(2):332-5. doi: 10.1002/lary.22397. Epub 2012 Jan 17.</citation>
    <PMID>22252988</PMID>
  </reference>
  <reference>
    <citation>Roy N, Stemple J, Merrill RM, Thomas L. Epidemiology of voice disorders in the elderly: preliminary findings. Laryngoscope. 2007 Apr;117(4):628-33.</citation>
    <PMID>17429872</PMID>
  </reference>
  <reference>
    <citation>Golub JS, Chen PH, Otto KJ, Hapner E, Johns MM 3rd. Prevalence of perceived dysphonia in a geriatric population. J Am Geriatr Soc. 2006 Nov;54(11):1736-9.</citation>
    <PMID>17087701</PMID>
  </reference>
  <reference>
    <citation>Gregory ND, Chandran S, Lurie D, Sataloff RT. Voice disorders in the elderly. J Voice. 2012 Mar;26(2):254-8. doi: 10.1016/j.jvoice.2010.10.024. Epub 2011 May 6.</citation>
    <PMID>21530163</PMID>
  </reference>
  <reference>
    <citation>Palmer AD, Newsom JT, Rook KS. How does difficulty communicating affect the social relationships of older adults? An exploration using data from a national survey. J Commun Disord. 2016 Jul-Aug;62:131-46. doi: 10.1016/j.jcomdis.2016.06.002. Epub 2016 Jun 22.</citation>
    <PMID>27420152</PMID>
  </reference>
  <reference>
    <citation>Holt-Lunstad J, Smith TB, Layton JB. Social relationships and mortality risk: a meta-analytic review. PLoS Med. 2010 Jul 27;7(7):e1000316. doi: 10.1371/journal.pmed.1000316. Review.</citation>
    <PMID>20668659</PMID>
  </reference>
  <reference>
    <citation>Marmor S, Horvath KJ, Lim KO, Misono S. Voice problems and depression among adults in the United States. Laryngoscope. 2016 Aug;126(8):1859-64. doi: 10.1002/lary.25819. Epub 2015 Dec 21.</citation>
    <PMID>26691195</PMID>
  </reference>
  <reference>
    <citation>Tay EY, Phyland DJ, Oates J. The effect of vocal function exercises on the voices of aging community choral singers. J Voice. 2012 Sep;26(5):672.e19-27. doi: 10.1016/j.jvoice.2011.12.014. Epub 2012 Jun 19.</citation>
    <PMID>22717496</PMID>
  </reference>
  <reference>
    <citation>Gorman S, Weinrich B, Lee L, Stemple JC. Aerodynamic changes as a result of vocal function exercises in elderly men. Laryngoscope. 2008 Oct;118(10):1900-3. doi: 10.1097/MLG.0b013e31817f9822.</citation>
    <PMID>18622308</PMID>
  </reference>
  <reference>
    <citation>Ziegler A, Verdolini Abbott K, Johns M, Klein A, Hapner ER. Preliminary data on two voice therapy interventions in the treatment of presbyphonia. Laryngoscope. 2014 Aug;124(8):1869-76. doi: 10.1002/lary.24548. Epub 2014 Jan 29.</citation>
    <PMID>24375313</PMID>
  </reference>
  <reference>
    <citation>Caskey CI, Zerhouni EA, Fishman EK, Rahmouni AD. Aging of the diaphragm: a CT study. Radiology. 1989 May;171(2):385-9.</citation>
    <PMID>2704802</PMID>
  </reference>
  <reference>
    <citation>Kim J, Sapienza CM. Implications of expiratory muscle strength training for rehabilitation of the elderly: Tutorial. J Rehabil Res Dev. 2005 Mar-Apr;42(2):211-24. Review.</citation>
    <PMID>15944886</PMID>
  </reference>
  <reference>
    <citation>Enright PL, Kronmal RA, Higgins MW, Schenker MB, Haponik EF. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest. 1994 Sep;106(3):827-34.</citation>
    <PMID>8082366</PMID>
  </reference>
  <reference>
    <citation>Nam DH, Lim JY, Ahn CM, Choi HS. Specially programmed respiratory muscle training for singers by using respiratory muscle training device (Ultrabreathe). Yonsei Med J. 2004 Oct 31;45(5):810-7.</citation>
    <PMID>15515190</PMID>
  </reference>
  <reference>
    <citation>Wingate JM, Brown WS, Shrivastav R, Davenport P, Sapienza CM. Treatment outcomes for professional voice users. J Voice. 2007 Jul;21(4):433-49. Epub 2006 Apr 3.</citation>
    <PMID>16581229</PMID>
  </reference>
  <reference>
    <citation>Baker S, Davenport P, Sapienza C. Examination of strength training and detraining effects in expiratory muscles. J Speech Lang Hear Res. 2005 Dec;48(6):1325-33.</citation>
    <PMID>16478374</PMID>
  </reference>
  <reference>
    <citation>Sapienza CM, Wheeler K. Respiratory muscle strength training: functional outcomes versus plasticity. Semin Speech Lang. 2006 Nov;27(4):236-44. Review.</citation>
    <PMID>17117350</PMID>
  </reference>
  <reference>
    <citation>Murry T. Subglottal pressure and airflow measures during vocal fry phonation. J Speech Hear Res. 1971 Sep;14(3):544-51.</citation>
    <PMID>5163888</PMID>
  </reference>
  <reference>
    <citation>Smitheran JR, Hixon TJ. A clinical method for estimating laryngeal airway resistance during vowel production. J Speech Hear Disord. 1981 May;46(2):138-46.</citation>
    <PMID>7253590</PMID>
  </reference>
  <reference>
    <citation>Laciuga H, Rosenbek JC, Davenport PW, Sapienza CM. Functional outcomes associated with expiratory muscle strength training: narrative review. J Rehabil Res Dev. 2014;51(4):535-46. doi: 10.1682/JRRD.2013.03.0076. Review.</citation>
    <PMID>25144167</PMID>
  </reference>
  <reference>
    <citation>Rosen CA, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the voice handicap index-10. Laryngoscope. 2004 Sep;114(9):1549-56.</citation>
    <PMID>15475780</PMID>
  </reference>
  <reference>
    <citation>Gillespie AI, Dastolfo C, Magid N, Gartner-Schmidt J. Acoustic analysis of four common voice diagnoses: moving toward disorder-specific assessment. J Voice. 2014 Sep;28(5):582-8. doi: 10.1016/j.jvoice.2014.02.002. Epub 2014 May 28.</citation>
    <PMID>24880672</PMID>
  </reference>
  <reference>
    <citation>Awan SN, Roy N, Jetté ME, Meltzner GS, Hillman RE. Quantifying dysphonia severity using a spectral/cepstral-based acoustic index: Comparisons with auditory-perceptual judgements from the CAPE-V. Clin Linguist Phon. 2010 Sep;24(9):742-58. doi: 10.3109/02699206.2010.492446.</citation>
    <PMID>20687828</PMID>
  </reference>
  <reference>
    <citation>Kempster GB, Gerratt BR, Verdolini Abbott K, Barkmeier-Kraemer J, Hillman RE. Consensus auditory-perceptual evaluation of voice: development of a standardized clinical protocol. Am J Speech Lang Pathol. 2009 May;18(2):124-32. doi: 10.1044/1058-0360(2008/08-0017). Epub 2008 Oct 16.</citation>
    <PMID>18930908</PMID>
  </reference>
  <reference>
    <citation>Etter NM, Hapner ER, Barkmeier-Kraemer JM, Gartner-Schmidt JL, Dressler EV, Stemple JC. Aging Voice Index (AVI): Reliability and Validity of a Voice Quality of Life Scale for Older Adults. J Voice. 2019 Sep;33(5):807.e7-807.e12. doi: 10.1016/j.jvoice.2018.04.006. Epub 2018 May 7.</citation>
    <PMID>29748025</PMID>
  </reference>
  <reference>
    <citation>Gartner-Schmidt J, Rosen C. Treatment success for age-related vocal fold atrophy. Laryngoscope. 2011 Mar;121(3):585-9. doi: 10.1002/lary.21122. Epub 2010 Aug 3.</citation>
    <PMID>21344441</PMID>
  </reference>
  <reference>
    <citation>Sauder C, Roy N, Tanner K, Houtz DR, Smith ME. Vocal function exercises for presbylaryngis: a multidimensional assessment of treatment outcomes. Ann Otol Rhinol Laryngol. 2010 Jul;119(7):460-7.</citation>
    <PMID>20734967</PMID>
  </reference>
  <reference>
    <citation>Fairbanks G. Voice and articulation drill book. 2nd ed. New York: Harper and Row; 1960.</citation>
  </reference>
  <reference>
    <citation>Statistics FIFoAR. Older Americans 2010: Key Indicators of Well-Being. US Government Printing Office. 2010.</citation>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <results_first_submitted>July 7, 2021</results_first_submitted>
  <results_first_submitted_qc>August 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 30, 2021</results_first_posted>
  <disposition_first_submitted>June 17, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>August 4, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 30, 2021</disposition_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Amanda Gillespie</investigator_full_name>
    <investigator_title>Assitant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voice Disorders</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>only de-identified data will be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>during and through data analysis</ipd_time_frame>
    <ipd_access_criteria>additional researchers may receive de-identified information only if a data use agreement has been executed.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03696576/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited for the study from September 2018 until March 2020.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PhoRTE</title>
          <description>This group will undergo standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
        </group>
        <group group_id="P2">
          <title>PhoRTE + EMST</title>
          <description>This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Soreness of throat after therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PhoRTE</title>
          <description>This group will undergo standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
        </group>
        <group group_id="B2">
          <title>PhoRTE + EMST</title>
          <description>This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.10" spread="7.91"/>
                    <measurement group_id="B2" value="75.22" spread="8.12"/>
                    <measurement group_id="B3" value="73.53" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Voice Handicap Index-10 (VHI-10) Score</title>
        <description>The Voice Handicap Index-10 (VHI-10) is a validated assessment instrument that quantifies patient perceptions of his or her own voice handicap. A lower score on the VHI-10 indicates perception of a lesser voice handicap than a high score. Scores range from 0 to 40.</description>
        <time_frame>At each study visit through study completion; Time 0 (therapy visit 1-Baseline), follow-up week 1 (therapy visit 2), follow-up week 2 (therapy visit 3),follow-up week 3 (therapy visit 4), follow-up week 5 (follow up visit)</time_frame>
        <population>Number of participants analyzed is different in each time point, due to difficulties bringing participants into the clinic because of COVID-19.</population>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Voice Handicap Index-10 (VHI-10) Score</title>
          <description>The Voice Handicap Index-10 (VHI-10) is a validated assessment instrument that quantifies patient perceptions of his or her own voice handicap. A lower score on the VHI-10 indicates perception of a lesser voice handicap than a high score. Scores range from 0 to 40.</description>
          <population>Number of participants analyzed is different in each time point, due to difficulties bringing participants into the clinic because of COVID-19.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.80" spread="6.94"/>
                    <measurement group_id="O2" value="17.45" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up-week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.85" spread="9.5"/>
                    <measurement group_id="O2" value="20.54" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up-week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.00" spread="9.86"/>
                    <measurement group_id="O2" value="17.00" spread="12.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up-week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.09" spread="9.76"/>
                    <measurement group_id="O2" value="15.67" spread="11.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up-week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.00" spread="11.07"/>
                    <measurement group_id="O2" value="10.17" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up-week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="10.86"/>
                    <measurement group_id="O2" value="10.50" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AVI Score at Baseline and Follow up (5 Weeks)</title>
        <description>The Aging Voice Index (AVI) is a validated instrument that measures quality of life in older adults with voice disorders. A higher score indicates worse quality of life. Scores range from 0 to 92.</description>
        <time_frame>At initial therapy visit (Baseline) and final follow up-visit (Follow up - week 5)</time_frame>
        <population>All participants were assessed for this outcome measure. 13 participants in the PhoRTE arm and 11 participants in the PhoRTE + EMST arm at baseline and follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>AVI Score at Baseline and Follow up (5 Weeks)</title>
          <description>The Aging Voice Index (AVI) is a validated instrument that measures quality of life in older adults with voice disorders. A higher score indicates worse quality of life. Scores range from 0 to 92.</description>
          <population>All participants were assessed for this outcome measure. 13 participants in the PhoRTE arm and 11 participants in the PhoRTE + EMST arm at baseline and follow up.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.54" spread="6.19"/>
                    <measurement group_id="O2" value="43.64" spread="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.13" spread="6.72"/>
                    <measurement group_id="O2" value="27.36" spread="8.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Expiratory Pressure (MEP)</title>
        <description>Maximum Expiratory Pressure (MEP) was measured using a handheld manometer (Micro Direct Respiratory Pressure Meter, MicroRPM, Med-Electronics, Beltsville, MD, United States) at baseline and after 5 weeks of therapy. Participants were instructed to blow with maximum force into the MicroRPM device over 10 trials, and the participant's best three trials were used to calculate their average MEP.</description>
        <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Expiratory Pressure (MEP)</title>
          <description>Maximum Expiratory Pressure (MEP) was measured using a handheld manometer (Micro Direct Respiratory Pressure Meter, MicroRPM, Med-Electronics, Beltsville, MD, United States) at baseline and after 5 weeks of therapy. Participants were instructed to blow with maximum force into the MicroRPM device over 10 trials, and the participant's best three trials were used to calculate their average MEP.</description>
          <units>cm H2O</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.08" spread="7.85"/>
                    <measurement group_id="O2" value="49.18" spread="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.32" spread="8.83"/>
                    <measurement group_id="O2" value="81.81" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phonatory Airflow in Speech at Baseline and 5 Weeks</title>
        <description>Aerodynamic measures were collected and analyzed via the Phonatory Aerodynamic System 6600 (PAS; PENTAX Medical, Montvale, NJ, United States) using the first four sentences of the Rainbow Passage. Aerodynamic measures included mean airflow during voicing and number of breaths taken. The PAS captured phonatory aerodynamic functioning using a pneumotach coupled to a facemask, with external microphone. During speech, expired air flows through the pneumotach, which consists of a stainless-steel mesh screen with pressure transducers on either side. The system calculates the pressure difference across the screen to determine airflow rate. The microphone is positioned at the end of the pneumotach and internally calibrated per system specifications to represent a mouth-to-microphone distance of 15 cm. The participant sat with the facemask held snugly over their nose and mouth while they read the first fou</description>
        <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Phonatory Airflow in Speech at Baseline and 5 Weeks</title>
          <description>Aerodynamic measures were collected and analyzed via the Phonatory Aerodynamic System 6600 (PAS; PENTAX Medical, Montvale, NJ, United States) using the first four sentences of the Rainbow Passage. Aerodynamic measures included mean airflow during voicing and number of breaths taken. The PAS captured phonatory aerodynamic functioning using a pneumotach coupled to a facemask, with external microphone. During speech, expired air flows through the pneumotach, which consists of a stainless-steel mesh screen with pressure transducers on either side. The system calculates the pressure difference across the screen to determine airflow rate. The microphone is positioned at the end of the pneumotach and internally calibrated per system specifications to represent a mouth-to-microphone distance of 15 cm. The participant sat with the facemask held snugly over their nose and mouth while they read the first fou</description>
          <units>Liters/second</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.05"/>
                    <measurement group_id="O2" value="0.18" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.07"/>
                    <measurement group_id="O2" value="0.12" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Breaths at Baseline and Follow up (5 Weeks)</title>
        <description>Aerodynamic measurement: mean number of breaths in reading of a standard passage (The Rainbow Passage).</description>
        <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Breaths at Baseline and Follow up (5 Weeks)</title>
          <description>Aerodynamic measurement: mean number of breaths in reading of a standard passage (The Rainbow Passage).</description>
          <units>number of breaths</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.17" spread="0.96"/>
                    <measurement group_id="O2" value="6.59" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.36" spread="1"/>
                    <measurement group_id="O2" value="5.52" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Cepstral Spectral Index of Dysphonia (CSID) Measurements While Reading Functional Phrases at Baseline and 5 Weeks</title>
        <description>Cepstral Spectral Index of Dysphonia (CSID) is a multifactorial estimate of dysphonia severity that correlates with an auditory perceptual rating of overall voice severity using a 0-100 visual analog scale. Components of the algorithm include the cepstral peak prominence and its standard deviation, the low to high spectral ratio and its standard deviation. Typically, CSID limits are 0-100, but very severe voices may exceed 100, and very periodic, normal voices may be less than 0.</description>
        <time_frame>Baseline (At initial therapy visit) and final follow up-visit (week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Cepstral Spectral Index of Dysphonia (CSID) Measurements While Reading Functional Phrases at Baseline and 5 Weeks</title>
          <description>Cepstral Spectral Index of Dysphonia (CSID) is a multifactorial estimate of dysphonia severity that correlates with an auditory perceptual rating of overall voice severity using a 0-100 visual analog scale. Components of the algorithm include the cepstral peak prominence and its standard deviation, the low to high spectral ratio and its standard deviation. Typically, CSID limits are 0-100, but very severe voices may exceed 100, and very periodic, normal voices may be less than 0.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.05" spread="7.15"/>
                    <measurement group_id="O2" value="28.85" spread="7.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.08" spread="8.57"/>
                    <measurement group_id="O2" value="20.7" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cepstral Spectral Index of Dysphonia (CSID) Measurements at Baseline and 5 Weeks</title>
        <description>Cepstral Spectral Index of Dysphonia (CSID) is a multifactorial estimate of dysphonia severity that correlates with an auditory perceptual rating of overall voice severity using a 0-100 visual analog scale. Components of the algorithm include the cepstral peak prominence and its standard deviation, the low to high spectral ratio and its standard deviation. Typically, CSID limits are 0-100, but very severe voices may exceed 100, and very periodic, normal voices may be less than 0.</description>
        <time_frame>Baseline (At initial therapy visit) and final follow up-visit (week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Cepstral Spectral Index of Dysphonia (CSID) Measurements at Baseline and 5 Weeks</title>
          <description>Cepstral Spectral Index of Dysphonia (CSID) is a multifactorial estimate of dysphonia severity that correlates with an auditory perceptual rating of overall voice severity using a 0-100 visual analog scale. Components of the algorithm include the cepstral peak prominence and its standard deviation, the low to high spectral ratio and its standard deviation. Typically, CSID limits are 0-100, but very severe voices may exceed 100, and very periodic, normal voices may be less than 0.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.93" spread="8.02"/>
                    <measurement group_id="O2" value="42.9" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.08" spread="10.39"/>
                    <measurement group_id="O2" value="41.56" spread="12.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Standard Reading Passage at Baseline and Follow up (5 Weeks)</title>
        <description>Aerodynamic measurement; mean duration to complete the reading of a standard passage (The Rainbow Passage).</description>
        <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Standard Reading Passage at Baseline and Follow up (5 Weeks)</title>
          <description>Aerodynamic measurement; mean duration to complete the reading of a standard passage (The Rainbow Passage).</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.23" spread="1.54"/>
                    <measurement group_id="O2" value="28.56" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.31" spread="1.84"/>
                    <measurement group_id="O2" value="24.93" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cepstral Peak Prominence at Baseline and 5 Weeks Follow up</title>
        <description>Acoustic measurement: Cepstral Peak Prominence and its standard deviation while reading functional phrases.</description>
        <time_frame>At initial therapy visit (Baseline) and final follow up-visit (after week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Cepstral Peak Prominence at Baseline and 5 Weeks Follow up</title>
          <description>Acoustic measurement: Cepstral Peak Prominence and its standard deviation while reading functional phrases.</description>
          <units>dB</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05" spread="0.98"/>
                    <measurement group_id="O2" value="7.13" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.32" spread="1.27"/>
                    <measurement group_id="O2" value="7.68" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cepstral Peak Prominence (CPP) Fundamental Frequency (F0) at Baseline and Follow up (5 Weeks)</title>
        <description>Acoustic measurement: CPP F0 while reading functional phrases.</description>
        <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Cepstral Peak Prominence (CPP) Fundamental Frequency (F0) at Baseline and Follow up (5 Weeks)</title>
          <description>Acoustic measurement: CPP F0 while reading functional phrases.</description>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.21" spread="14.51"/>
                    <measurement group_id="O2" value="167.04" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.97" spread="15.81"/>
                    <measurement group_id="O2" value="178.09" spread="17.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Fundamental Frequency in Sentence at Baseline and at 5 Weeks</title>
        <description>Aerodynamic measurement: mean F0 in reading of a standard passage (The Rainbow Passage).</description>
        <time_frame>At initial therapy visit (Baseline) and final follow up-visit (week 5)</time_frame>
        <population>All participants were assessed for this outcome measure. 13 participants in the PhoRTE arm and 11 participants in the PhoRTE + EMST arm, at baseline and follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Fundamental Frequency in Sentence at Baseline and at 5 Weeks</title>
          <description>Aerodynamic measurement: mean F0 in reading of a standard passage (The Rainbow Passage).</description>
          <population>All participants were assessed for this outcome measure. 13 participants in the PhoRTE arm and 11 participants in the PhoRTE + EMST arm, at baseline and follow up.</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.31" spread="8.66"/>
                    <measurement group_id="O2" value="152.78" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.09" spread="10.15"/>
                    <measurement group_id="O2" value="156.81" spread="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vocal Intensity at Baseline and Follow up</title>
        <description>Acoustic measurement: mean vocal intensity in dB SPL while reading functional phrases.</description>
        <time_frame>At initial therapy visit (baseline) and final follow up-visit (week 5)</time_frame>
        <population>All participants were assessed for this outcome measure. 13 participants in the PhoRTE arm and 11 participants in the PhoRTE + EMST arm, at baseline and follow up.</population>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Vocal Intensity at Baseline and Follow up</title>
          <description>Acoustic measurement: mean vocal intensity in dB SPL while reading functional phrases.</description>
          <population>All participants were assessed for this outcome measure. 13 participants in the PhoRTE arm and 11 participants in the PhoRTE + EMST arm, at baseline and follow up.</population>
          <units>dB SPL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.22" spread="1.49"/>
                    <measurement group_id="O2" value="76.48" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.06" spread="1.95"/>
                    <measurement group_id="O2" value="73.56" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change In Overall Voice Severity at 5 Weeks</title>
        <description>Overall voice severity determined by Consensus Auditory Perceptual Evaluation - Voice (CAPE-V) score provided by blinded raters. The visual analog scale for overall voice severity used. Minimum score = 0, Maximum score = 100. Higher values indicate worse voice.</description>
        <time_frame>At initial therapy visit and final follow up-visit, after week 5</time_frame>
        <population>Auditory perceptual measurements of overall voice severity were not collected, thus not analyzed, due to having to convert to tele-health due to COVID-19 pandemic.</population>
        <group_list>
          <group group_id="O1">
            <title>PhoRTE</title>
            <description>This group received standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
          <group group_id="O2">
            <title>PhoRTE + EMST</title>
            <description>This group received standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change In Overall Voice Severity at 5 Weeks</title>
          <description>Overall voice severity determined by Consensus Auditory Perceptual Evaluation - Voice (CAPE-V) score provided by blinded raters. The visual analog scale for overall voice severity used. Minimum score = 0, Maximum score = 100. Higher values indicate worse voice.</description>
          <population>Auditory perceptual measurements of overall voice severity were not collected, thus not analyzed, due to having to convert to tele-health due to COVID-19 pandemic.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PhoRTE</title>
          <description>This group will undergo standard PhoRTE therapy.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
        </group>
        <group group_id="E2">
          <title>PhoRTE + EMST</title>
          <description>This group will undergo standard PhoRTE therapy with the addition of expiratory muscle strength training using the EMST device.&#xD;
EMST: Training of the respiratory system muscles using the EMST device.&#xD;
PhoRTE: Completing of PhoRTE voice therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sandeep Shelly</name_or_title>
      <organization>Emory University</organization>
      <phone>404-686-4206</phone>
      <email>SSHELLY@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

